Invo BioScience Income After Taxes 2010-2024 | NAYA
Invo BioScience income after taxes from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Invo BioScience Annual Income After Taxes
(Millions of US $) |
| 2023 |
$-8 |
| 2022 |
$-11 |
| 2021 |
$-7 |
| 2020 |
$-8 |
| 2019 |
$-2 |
| 2018 |
$-3 |
| 2017 |
$-1 |
| 2016 |
$-2 |
| 2015 |
$-5 |
| 2014 |
$-2 |
| 2013 |
$-1 |
| 2012 |
$-1 |
| 2011 |
$-1 |
| 2010 |
$-0 |
| 2009 |
$-5 |
Invo BioScience Quarterly Income After Taxes
(Millions of US $) |
| 2024-06-30 |
$-2 |
| 2024-03-31 |
$-2 |
| 2023-12-31 |
$-2 |
| 2023-09-30 |
$-1 |
| 2023-06-30 |
$-2 |
| 2023-03-31 |
$-3 |
| 2022-12-31 |
$-3 |
| 2022-09-30 |
$-3 |
| 2022-06-30 |
$-3 |
| 2022-03-31 |
$-3 |
| 2021-12-31 |
$0 |
| 2021-09-30 |
$-2 |
| 2021-06-30 |
$-2 |
| 2021-03-31 |
$-2 |
| 2020-12-31 |
$-4 |
| 2020-09-30 |
$-2 |
| 2020-06-30 |
$-1 |
| 2020-03-31 |
$-1 |
| 2019-12-31 |
$-1 |
| 2019-09-30 |
$-1 |
| 2019-06-30 |
$-0 |
| 2019-03-31 |
$-0 |
| 2018-12-31 |
$-1 |
| 2018-09-30 |
$-0 |
| 2018-06-30 |
$-2 |
| 2018-03-31 |
$-0 |
| 2017-12-31 |
$-0 |
| 2017-09-30 |
$-0 |
| 2017-06-30 |
$-0 |
| 2017-03-31 |
$-0 |
| 2016-12-31 |
$-0 |
| 2016-09-30 |
$-0 |
| 2016-06-30 |
$-1 |
| 2016-03-31 |
$-0 |
| 2015-12-31 |
$-0 |
| 2015-09-30 |
$-0 |
| 2015-06-30 |
$-4 |
| 2015-03-31 |
$-0 |
| 2011-12-31 |
$-0 |
| 2011-09-30 |
$-0 |
| 2011-06-30 |
$-0 |
| 2011-03-31 |
$-0 |
| 2010-12-31 |
$-0 |
| 2010-09-30 |
$-0 |
| 2010-06-30 |
$-0 |
| 2010-03-31 |
$1 |
| 2009-12-31 |
$-0 |
| 2009-09-30 |
$-3 |
| 2009-06-30 |
$-0 |
| 2009-03-31 |
$-1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.004B |
$0.003B |
|
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.
|
